9/18/2025

BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.

Source: Yahoo

9/18/2025

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients living with neurological disorders. CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therape

Source: Yahoo

9/18/2025

The postpartum depression marketing authorisation in the EU follows approvals for the drug in the US and the UK over the past two years.

Source: Yahoo

9/18/2025

The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.

Source: Yahoo

9/18/2025

Biogen to Buy Alcyone Therapeutics for Initial $85 Million

Source: MarketWatch

9/17/2025

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of this new therapeutic approach introduces an oral, 14-day treatment specifically indicated for PPDThe EC approval of ZURZUVAE is based on the SKYLARK study, which demonstrated rapid relief from depressive symptoms as early as day 3 and sustained through day 45 comp

Source: Yahoo

9/17/2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen (NASDAQ:BIIB).

Source: Yahoo

9/16/2025

Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (NASDAQ:BIIB) reported total revenue of $2.6 billion in its fiscal Q2 2025 results, […]

Source: Yahoo

9/16/2025

Biogen recently announced that the U.S. FDA has accepted its investigational new drug (IND) application for BIIB142, an IRAK4 degrader developed in partnership with C4 Therapeutics, for exploration in autoimmune diseases. This milestone highlights the growing validation of C4 Therapeutics' targeted protein degradation platform and entitles the company to a US$2 million payment once clinical dosing begins. We'll explore how the FDA acceptance of Biogen's IND application for BIIB142...

Source: Yahoo

9/15/2025

Biogen Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

9/15/2025

Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. According to H.C. Wainwright, the lupus treatments litifilimab […]

Source: Yahoo

9/12/2025

Although Biogen has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Source: Yahoo

9/12/2025

Biogen Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

9/11/2025

Biogen Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

9/11/2025

The deal includes AI-powered software for detecting known side effects of recently launched Alzheimer’s drugs.

Source: Yahoo

9/10/2025

Alzheimer’s market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China dominate sales, with future expansions anticipated, requiring strategic in-licensing, partnerships, and innovation to capture growing demand.Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offer

Source: Yahoo

9/9/2025

A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.

Source: Yahoo

9/8/2025

Get insights from Biogen's CEO on growth strategies, Alzheimer's market expansion, and

Source: SeekingAlpha

9/8/2025

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.

Source: SeekingAlpha

9/6/2025

In recent days, Biogen and its partners announced the FDA approval and October launch of LEQEMBI Iqlik, a subcutaneous, at-home formulation for early Alzheimer's disease, along with new positive clinical data for zorevunersen in Dravet syndrome presented at a major epilepsy congress. These updates highlight growing momentum in the advancement of therapies for challenging neurological conditions, potentially expanding Biogen's addressable patient population and reinforcing the company’s focus...

Source: Yahoo